home / stock / xphy:cc / xphy:cc news


XPHY:CC News and Press, Xphyto Therapeutics Corp. - Common Shares

Stock Information

Company Name: Xphyto Therapeutics Corp. - Common Shares
Stock Symbol: XPHY:CC
Market: CNQC

Menu

XPHY:CC XPHY:CC Quote XPHY:CC Short XPHY:CC News XPHY:CC Articles XPHY:CC Message Board
Get XPHY:CC Alerts

News, Short Squeeze, Breakout and More Instantly...

XPHY:CC - CSE Bulletin: Name and Symbol Change - XPhyto Therapeutics Corp. (XPHY)

Toronto, Ontario--(Newsfile Corp. - Le 10 novembre/November 2022) - XPhyto Therapeutics Corp. (XPHY) has announced a name and symbol change to BioNxt Solutions Inc. (BNXT). Shares will begin trading under the new name and symbol and with a new CUSIP number on November 14, 2022. Disclos...

XPHY:CC - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Changes Name to BioNxt Solutions Inc.

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has announced a name change. According to the company, effective next Monday, Nov. 14, 2022, the company’s name will change from XPhyto Therapeutics Corp. to BioNxt Solutions Inc. Along with the name change, the com...

XPHY:CC - XPhyto Announces Name Change to BioNxt Solutions Inc.

VANCOUVER, BC / ACCESSWIRE / November 10, 2022 / XPhyto Therapeutics Corp. (" XPhyto " or the " Company ") (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that effective November 14, 2022, the Company's name will change from "XPhyto Therapeutics Corp." to " BioNxt Solutions Inc. ". A...

XPHY:CC - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Major Milestone on Path to Commercialization of Lead Product

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today reported the results of its Rotigotine transdermal (“TDS”) patch human skin cadaver study and dissolution data. The company’s Rotigotine patch is based on the TDS platform technology developed by Vektor Ph...

XPHY:CC - XPhyto Reports Excellent Rotigotine In-Vitro/Ex-Vivo Results for Parkinson's Disease Treatment

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / October 18, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)( FSE:4XT) ("XPhyto" or the "Company") is pleased to report the results of its Rotigotine transdermal ("TDS") patch human skin cadaver study and dissolution data. The C...

XPHY:CC - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Completion of Rotigotine TDS Patch Study

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today provided a product development report on its Rotigotine transdermal (“TDS”) patch. According to the update, the company’s Rotigotine patch is based on TDS platform technology developed by its wholly owned ...

XPHY:CC - XPhyto Completes Rotigotine Transdermal Patch Optimization and Comparative Skin Absorption Study

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / October 11, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a product development report on its Rotigotine transdermal ("TDS") patch. The Company's Rotigotine patch is ...

XPHY:CC - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE:4XT) Inks LOI to Identify Manufacturing, Strategic Business Opportunities

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has signed a nonbinding letter of intent ("LOI") with a U.S.-based thin film manufacturing firm. The collaboration between the two companies will focus on evaluating potential business synergies for manufacturing, import/export...

XPHY:CC - XPhyto Signs Letter of Intent for US Manufacturing and Strategic Business Opportunities

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / October 4, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)( OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to report that it has signed a non-binding Letter of Intent ("LOI") to identify and assess potential business synergies...

XPHY:CC - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Patent Application for Novel Psychedelic Compound Library

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE:4XT) has filed a patent application covering a significant library of novel psychedelic compounds. According to the announcement, each compound included in the filing is designed to provide specific alterations in their respective bi...

Next 10